2024
The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers
Mustafa S, Jansen C, Jani Y, Evans S, Zhuang T, Brown J, Nazha B, Master V, Bilen M. The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers. Biomarker Insights 2024, 19: 11772719241254179. PMID: 38827239, PMCID: PMC11143877, DOI: 10.1177/11772719241254179.Peer-Reviewed Original ResearchImmune-related adverse eventsImmune checkpoint inhibitorsResponse to immunotherapyAdverse eventsTreatment of genitourinary malignanciesImmune checkpoint blockadeSelection of therapySignificant side effectsCheckpoint blockadeCheckpoint inhibitorsGU malignanciesGenitourinary malignanciesPatient tumorsTreatment landscapeReview of biomarkersGenitourinary cancersGU tumorsPreclinical studiesPrognostic toolSide effectsTherapyBiomarker developmentTumorPatientsImmunotherapy
2022
CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor
Prokhnevska N, Cardenas M, Valanparambil R, Sobierajska E, Barwick B, Jansen C, Reyes Moon A, Gregorova P, delBalzo L, Greenwald R, Bilen M, Alemozaffar M, Joshi S, Cimmino C, Larsen C, Master V, Sanda M, Kissick H. CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity 2022, 56: 107-124.e5. PMID: 36580918, PMCID: PMC10266440, DOI: 10.1016/j.immuni.2022.12.002.Peer-Reviewed Original ResearchConceptsTumor-draining lymph nodesCD8<sup>+</sup> T cell activationT cell activationCD8<sup>+</sup> T cellsStem-like cellsT cellsCell activationEffector differentiationLymph nodesTumor-specific CD8<sup>+</sup> T cellsActivated CD8<sup>+</sup> T cellsAnti-tumor T cell responsesTumor-draining lymph node cellsCD8+ T cell activationCo-stimulationT cell responsesAntigen-presenting cellsMurine tumor modelsResponse to cancerEffector phenotypeTumor immunotherapyTumor modelTumorCell responsesAcute viruses
2020
The immunosuppressive phenotype of tumor-infiltrating neutrophils is associated with obesity in kidney cancer patients
Margaroli C, Cardenas M, Jansen C, Reyes A, Hosseinzadeh F, Hong G, Zhang Y, Kissick H, Tirouvanziam R, Master V. The immunosuppressive phenotype of tumor-infiltrating neutrophils is associated with obesity in kidney cancer patients. OncoImmunology 2020, 9: 1747731. PMID: 32313729, PMCID: PMC7153842, DOI: 10.1080/2162402x.2020.1747731.Peer-Reviewed Original ResearchConceptsKidney cancer patientsTumor microenvironmentArginase-1Tumor tissuesActivated phenotypeCancer patientsMyeloid-derived suppressor cellsImmature-like phenotypeTumor-infiltrating neutrophilsTumor-associated neutrophilsEnzyme arginase-1Associated with obesityPhenotype of neutrophilsAdipose tissue distributionMetabolic statePatient's metabolic stateSuppressor cellsImmunosuppressive phenotypeImmunosuppressive roleTumor progressionTumor neutrophilsDisease progressionCirculating neutrophilsTumorGranule release
2019
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
Jansen C, Prokhnevska N, Master V, Sanda M, Carlisle J, Bilen M, Cardenas M, Wilkinson S, Lake R, Sowalsky A, Valanparambil R, Hudson W, McGuire D, Melnick K, Khan A, Kim K, Chang Y, Kim A, Filson C, Alemozaffar M, Osunkoya A, Mullane P, Ellis C, Akondy R, Im S, Kamphorst A, Reyes A, Liu Y, Kissick H. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 2019, 576: 465-470. PMID: 31827286, PMCID: PMC7108171, DOI: 10.1038/s41586-019-1836-5.Peer-Reviewed Original ResearchConceptsCD8 T cellsStem-like CD8 T cellsT cellsStem-like T cellsCD8 T cell infiltrationCD8 T cell responsesMechanism of immune escapeTumor-infiltrating lymphocytesT cell infiltrationT cell responsesStem-like cellsSurvival benefitImmune nicheProgressive diseaseImmune escapeTumor typesTumorCD8Human cancersDifferentiation processLymphocytesPatientsCancerInfiltrationSurvival
2018
The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer
Jansen C, Prokhnevska N, Kissick H. The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer. Urologic Oncology Seminars And Original Investigations 2018, 37: 543-555. PMID: 30446449, PMCID: PMC6513714, DOI: 10.1016/j.urolonc.2018.10.011.Peer-Reviewed Original Research